NorthWest Biotherapeutics Inc (NWBO)

[FeMike]

I bet it is the Win-Glo programme.

Looks like it may involve DCVax-L, amongst other candidates. This looks like it may be one of the collaborations NWBO was talking about in the last Q.

(edited: took out the 'likely' and 'definitely' as this is certainly speculation and nothing "definite" about it - but I think it's a solid guess)

The Win-Glio Programme of clinical trials improves the effectiveness of cancer drugs by using them alongside drugs that modulate the immune system.

Both types of drugs have already been licensed or are in clinical development.

It’s known how these drugs work. It’s known what they do to tumours, what the correct dose is, and the potential side-effects. This isn’t starting from scratch.

Immunotherapy has already been successfully used with melanoma (skin cancer) patients. Because melanoma shares similarities to glioblastoma brain cancer there is every chance these successes can be replicated.

The Win-Glio programme, launched at the end of 2023, is developing its first trial for early 2025. It will involve ten patients who are due to have surgery for glioblastoma. These patients will receive immunotherapy drugs to target the glioblastoma cancer. There will be multiple trials, each using different immunotherapy drugs. A significant response rate in one of the cohorts of patients will allow further patients to be enrolled into this group to give a statistically significant number of patients for further analysis.

The Win-Glio Programme is led by Dr Paul Mulholland. Paul is a medical oncologist who exclusively treats brain cancer. He is a consultant at University College Hospital, the National Hospital for Neurology and Neurosurgery (part of UCLH).